Northwest Biotherapeutics Announces Development Completed for Initial Production Capacity of Sawston, UK Facility
Application for MHRA Regulatory Certification of Facility In Preparation
News provided by
Share this article
Share this article
BETHESDA, Md., March 16, 2021 /PRNewswire/ Northwest Biotherapeutics (OTCQB: NWBO) ( NW Bio ), a biotechnology company developing DCVax
® personalized immune therapies for solid tumor cancers, today announced that development of the initial production capacity of the Company s Sawston, UK advanced manufacturing facility has been completed and the facility is now in the final stages of preparation for an application for certification by the UK Medicines and Health Products Regulatory Authority ( MHRA ).